Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-Like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex) in Postmenopausal Patients With Advanced Hormono-Dependent Breast Cancer.

Next Previous
Search
Trial Profile

Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-Like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex) in Postmenopausal Patients With Advanced Hormono-Dependent Breast Cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veligrotug (Primary) ; Fulvestrant
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 27 Feb 2024 According to a Viridian Therapeutics media release, company plans to present encore VRDN-001 Phase 2 clinical data from this trial at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) to be held March 2-7, 2024 in Honolulu, Hawaii.
    • 09 Apr 2022 This trial has been completed in Spain (End Date: 10 Nov 2010) according to European Clinical Trials Database record
    • 01 Apr 2022 This trial has been completed in France (End Date: 10 Nov 2010) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top